Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
S., Kim, D
Orforglipron, Lilly's once-daily oral non-peptide GLP-1 agonist, helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose in a late-stage trial
Bellanti et al., 2022
The FDA and European Medicines Agency both reviewed the data on suicidality concerns and concluded theres no causal link between GLP-1 receptor agonist use and suicidality
Early Symptoms Symptoms may begin during the first weeks or after a research dose increase
US$ 28.80
US$ 28.27
US$ 24.42
US$ 27.39
US$ 28.21
US$ 22.16
US$ 29.53
US$ 20.54
US$ 29.28
US$ 24.60
